Knight Cancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, OR, 97201, USA.
Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, 97201, USA.
Commun Biol. 2021 Sep 24;4(1):1130. doi: 10.1038/s42003-021-02651-8.
Cellular circulating biomarkers from the primary tumor such as circulating tumor cells (CTCs) and circulating hybrid cells (CHCs) have been described to harbor tumor-like phenotype and genotype. CHCs are present in higher numbers than CTCs supporting their translational potential. Methods for isolation of CHCs do not exist and are restricted to low-throughput, time consuming, and biased methodologies. We report the development of a label-free dielectrophoretic microfluidic platform facilitating enrichment of CHCs in a high-throughput and rapid fashion by depleting healthy peripheral blood mononuclear cells (PBMCs). We demonstrated up to 96.5% depletion of PBMCs resulting in 18.6-fold enrichment of cancer cells. In PBMCs from pancreatic adenocarcinoma patients, the platform enriched neoplastic cells identified by their KRAS mutant status using droplet digital PCR with one hour of processing. Enrichment was achieved in 75% of the clinical samples analyzed, establishing this approach as a promising way to non-invasively analyze tumor cells from patients.
原发性肿瘤的细胞循环生物标志物,如循环肿瘤细胞(CTCs)和循环杂交细胞(CHCs),被描述为具有肿瘤样表型和基因型。CHCs 的数量高于 CTCs,支持其转化潜力。目前还没有分离 CHCs 的方法,而且这些方法受到低通量、耗时和有偏向性的方法的限制。我们报告了一种无标记的介电泳微流控平台的开发,该平台通过耗尽健康的外周血单核细胞(PBMCs),以高通量和快速的方式富集 CHCs。我们证明了 PBMCs 的耗竭率高达 96.5%,从而使癌细胞的富集倍数达到 18.6 倍。在胰腺腺癌患者的 PBMCs 中,该平台使用液滴数字 PCR 对其 KRAS 突变状态进行分析,在一小时的处理时间内富集了肿瘤细胞。在分析的 75%的临床样本中实现了富集,这为非侵入性地从患者中分析肿瘤细胞提供了一种很有前途的方法。